share_log

BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

Biolase(納斯達克：Biol)現在由StockNews.com的分析師報道
Financial News Live ·  2022/11/28 15:01

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research note issued to investors on Friday. The firm issued a sell rating on the medical technology company's stock.

斯托克新聞網在週五發佈給投資者的一份研究報告中開始報道納斯達克(BIOLASE：BIOL-GET Rating)的股票。該公司對這家醫療技術公司的股票發佈了賣出評級。

Other analysts have also issued research reports about the stock. Benchmark cut their price objective on shares of BIOLASE to $7.00 in a research note on Wednesday, November 16th. Ascendiant Capital Markets cut their price objective on shares of BIOLASE to $14.00 in a research note on Wednesday, November 16th. Finally, Maxim Group dropped their price target on shares of BIOLASE from $10.00 to $5.00 in a research report on Friday, November 11th.

其他分析師也發佈了有關該股的研究報告。11月16日星期三，Benchmark在一份研究報告中將BIOLASE的股價目標下調至7.00美元。在11月16日星期三的一份研究報告中，Ascaldiant Capital Markets將BIOLASE的股票目標價下調至14.00美元。最後，Maxim Group在11月11日星期五的一份研究報告中將BIOLASE的股票目標價從10.00美元下調至5.00美元。

Get
到達
BIOLASE
生物酶
alerts:
警報：

BIOLASE Stock Performance

Biolase股票表現

BIOL opened at $1.02 on Friday. BIOLASE has a 52-week low of $0.93 and a 52-week high of $13.83. The company has a quick ratio of 1.27, a current ratio of 2.46 and a debt-to-equity ratio of 0.92. The company has a market cap of $7.25 million, a P/E ratio of -0.28 and a beta of 1.45. The firm's 50-day moving average price is $2.01 and its 200-day moving average price is $3.51.

Biol上週五開盤報1.02美元。Biolase的52周低點為0.93美元，52周高位為13.83美元。該公司的速動比率為1.27，流動比率為2.46，債務權益比率為0.92。該公司市值為725萬美元，市盈率為-0.28，貝塔係數為1.45。該公司的50日移動均線價格為2.01美元，200日移動均線價格為3.51美元。

Institutional Trading of BIOLASE

BIOLASE的機構交易

Institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of BIOLASE in the second quarter valued at about $118,000. Capital Wealth Alliance LLC acquired a new stake in shares of BIOLASE in the second quarter valued at about $51,000. Commonwealth Equity Services LLC grew its position in shares of BIOLASE by 117.8% in the first quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock valued at $35,000 after purchasing an additional 54,650 shares during the period. Essex Investment Management Co. LLC grew its position in shares of BIOLASE by 62.3% in the third quarter. Essex Investment Management Co. LLC now owns 105,318 shares of the medical technology company's stock valued at $256,000 after purchasing an additional 40,440 shares during the period. Finally, Perkins Capital Management Inc. grew its position in shares of BIOLASE by 11.6% in the third quarter. Perkins Capital Management Inc. now owns 132,070 shares of the medical technology company's stock valued at $321,000 after purchasing an additional 13,770 shares during the period. Institutional investors and hedge funds own 21.21% of the company's stock.
機構投資者最近調整了對該股的持有量。Citadel Advisors LLC在第二季度收購了BIOLASE的新股份，價值約11.8萬美元。Capital Wealth Alliance LLC在第二季度收購了BIOLASE的新股份，價值約5.1萬美元。英聯邦股票服務有限責任公司在第一季度將其在BIOLASE股票的頭寸增加了117.8%。在此期間又購買了54,650股後，Federal Equity Services LLC現在擁有101,046股這家醫療技術公司的股票，價值35,000美元。埃塞克斯投資管理公司第三季度對BIOLASE股票的持倉增加了62.3%。埃塞克斯投資管理公司目前持有這家醫療技術公司105,318股股票，價值25.6萬美元，在此期間又購買了40,440股。最後，珀金斯資本管理公司(Perkins Capital Management Inc.)在第三季度將其在BIOLASE股票的持倉增加了11.6%。珀金斯資本管理公司目前持有這家醫療技術公司132,070股股票，價值321,000美元，在此期間又購買了13,770股。機構投資者和對衝基金持有該公司21.21%的股票。

BIOLASE Company Profile

Biolase公司簡介

(Get Rating)

(獲取評級)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Biolase公司與其子公司一起，在美國和國際上為牙科醫生及其患者開發、製造、營銷和銷售激光系統。它的牙科激光系統允許牙醫、牙周病醫生、牙髓醫生、口腔外科醫生和其他牙科專家執行一系列微創牙科手術，如美容、修復和複雜的外科應用。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
  • Best Buy Proves Brick and Mortar is Here to Stay
  • MarketBeat: Week in Review 11/21 – 11/25
  • Three CBD Stocks to Dominate a Budding Industry
  • Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
  • Institutional Support for Analog Devices Remains High
  • 免費獲取StockNews.com關於BIOLASE的研究報告(Biol)
  • 百思買證明磚頭和砂漿將繼續存在
  • MarketBeat：回顧一週11/21-11/25
  • 三隻CBD股票將主宰一個萌芽行業
  • Salesforce裁員，儘管面臨挑戰，但收入強勁
  • 機構對ADI的支持仍然很高

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.

接受《BIOLASE日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對BIOLASE和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論